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Introduction
Many patients on anti-IL-1 therapy are unable to stop
treatment prior to conception or during pregnancy but
little data exist regarding safety. We report the outcomes
of 20 IL-1 inhibitor exposed pregnancies in 18 women
from 7 countries (including the first data on canakinu-
mab exposed pregnancy) and paternal exposure to ana-
kinra or canakinumab at conception.
Objectives
To collate data on outcomes of IL-1 inhibitor exposed
pregnancies.
Patients and methods
A standardised data collection sheet was sent to clini-
cians known to treat SAID. Responses were collated and
analyzed retrospectively.
Results
We received data on 20 pregnancies born to 18 women
(Diagnoses: CAPS (11), AOSD (2), TRAPS (2), FMF (2),
and Idiopathic Pericarditis (1)).
4 pregnancies were exposed to canakinumab with the-
oretical exposure up to 18 weeks; 18 were exposed to
anakinra (2 were exposed to both agents).
All pregnancies reported were completed. The median
gestation at delivery was 38+4 weeks (range 35+1 to 41).
APGAR score was >9 in all recorded cases, birth weight
range 2.02-3.94 kilos.
Two congenital abnormalities were reported in a sin-
gle infant; growth hormone deficiency due to ectopic
neurohypophysis and unilateral renal agenesis in a boy
born to a mother with active AOSD at conception trea-
ted with anakinra from 9 weeks gestation.
7 babies were breast fed by mothers receiving anakinra
(range 3 - 40 weeks). None have reported infections or
developmental abnormalities.
A total of 13 babies were born to 10 fathers treated
with either anakinra (5) or canakinumab (8) at concep-
tion with no reported abnormalities.
Conclusion
This is the largest study to date of pregnancy outcomes
in parents receiving anti-IL1 therapies. Overall the data
are reassuring but numbers remain small.
Based on available data we currently advise precon-
ception planning, with the risks and benefits of therapy
individually discussed with potential parents. The data
regarding canakinumab are limited and our advice is to
switch to the more physiological anakinra, ideally prior
to conception. Whilst anakinra is detectable in breast
milk the data from 7 infants suggests it has no deleter-
ious effects.
The significance of unilateral renal agenesis in a foetus
exposed to anakinra is uncertain given a previous report
of fatal bilateral renal agenesis in utero of a twin foetus
exposed to anakinra (Chang et al., Arthritis & Rheuma-
tology 2014). This requires further investigation, and
there is a need for the SAIDs community to develop a
registry in order to provide the best information for
patients.
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